Today
0.00%
5 Days
-14.57%
1 Month
+38.03%
6 Months
-59.92%
Year to Date
-34.28%
1 Year
-42.96%
Hims & Hers Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 25 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 25.38.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Media Coverage
TradingKey - Shares of Hims & Hers Health (HIMS.US) surged nearly 64% cumulatively over the first three trading days of this week, with an intraday rally of over 10% on Wednesday.

Hims & Hers' subscription-based business model, coupled with tailored treatment regimens, allows users to maintain lasting engagement, a critical aspect of the company’s growth narrative and a reason why some see Hims & Hers stock as a play on long-term digital health as opposed to a traditional pha

TradingKey - Despite the whole controversy with NVO, we believe HIMS is able to achieve 6 million subscribers and $6 billion of revenue by 2030, due to the large opportunity of growth for the telehealth industry, early investments in logistics capabilities and ability to upsell their patients.

Explore the exciting world of Hims & Hers (NYSE: HIMS) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

TradingKey - The stock market is sending mixed messages about Hims & Hers Health (HIMS). On the plus side, the shares are trading higher by approximately 16% for the day, continuing a red-hot YTD run; on the other, the stock looks overvalued on paper with GAAP P/E and EV/EBITDA multiples several tim



Related Instruments
Popular Symbols